CONJUALL
LIVE

Serial Number

97191384

Owner

LEGOCHEM BIOSCIENCES, INC.

Attorney

Corey K. Cho

Filing Date

Dec 27, 2021

Add to watchlist:

No watchlists yet
View on USPTO

CONJUALL Trademark

Serial Number: 97191384 • Registration: 7477524

CONJUALL is a trademark filed by LEGOCHEM BIOSCIENCES, INC. on December 27, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

LEGOCHEM BIOSCIENCES, INC.

8-26, Munpyeongseo-ro, Daedeok-gu
Daejeon 34302 , KR

Entity Type: 03

Trademark Details

Filing Date

December 27, 2021

Registration Date

August 20, 2024

Published for Opposition

June 4, 2024

Goods & Services

Medicinal preparations for prevention and treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases, namely, antibodies, antibody conjugates and active ingredients and antibody conjugates; chemical reagents for medical use, especially chemical reagents for linking molecules for medical use; colostral antibodies and the chemical modifications and conjugates thereof for medical purposes and medical laboratory tests; drug delivery agents consisting of compounds that facilitate delivery of pharmaceuticals for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biological preparations for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; Chemical preparations for pharmaceutical purposes for the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical pharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; medical molecular diagnostic reagents for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; biopharmaceuticals for use in relation to the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases; pharmaceutical preparations for treatment of rare diseases

Scientific study and research in the field(s) of research on the subject of pharmaceuticals; development of pharmaceutical preparations and medicines; medical and pharmaceutical research services; biological research and analysis; chemical research and analysis; biochemical research and analysis; and scientific research in the nature of conducting clinical trials for others

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 20, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 20, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 4, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 4, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 15, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 2, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 2, 2024 CRFA
ASSIGNED TO LIE
May 2, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 12, 2023 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 27, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 27, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 27, 2023 REAP
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 14, 2023 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 14, 2023 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 14, 2023 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 17, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 17, 2023 GNSL
SUSPENSION LETTER WRITTEN
Mar 17, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 22, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 22, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 29, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 29, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 28, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 4, 2022 NWOS
NEW APPLICATION ENTERED
Dec 30, 2021 NWAP